import streamlit as st
import google.generativeai as genai

# --- ğŸ¥ å©¦ç™Œè‡¨åºŠå°èˆªèˆ‡ AI æ±ºç­–ç³»çµ± (2026 å°ˆå®¶å¯¦è­‰æ•¸æ“šå…¨æ–¹ä½æ“´å……ç‰ˆ) ---
st.set_page_config(page_title="å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ±", layout="wide")

st.markdown("""
    <style>
    @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;700;900&family=Roboto:wght@400;700;900&display=swap');
    
    /* === æ¥µè‡´ç·Šç·»åŒ– UIï¼šå¾¹åº•æ¶ˆé™¤ç•™ç™½ === */
    html, body, [class*="css"] {
        font-family: 'Noto Sans TC', 'Roboto', sans-serif;
        background-color: #F0F4F7;
        color: #1A1A1A;
        font-size: 19px !important;
        line-height: 1.1;
    }

    .main-title {
        font-size: 32px !important; font-weight: 900; color: #004D40;
        padding: 5px 0; border-bottom: 3px solid #4DB6AC; margin-bottom: 5px;
    }

    /* å¤§éšæ®µæ–¹å¡Šï¼šé«˜åº¦è‡ªé©æ‡‰ï¼Œæ¶ˆé™¤æ¨™é¡Œä¸‹æ–¹ç•™ç™½ */
    .big-stage-card {
        border-radius: 10px; padding: 0px; 
        box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        border: 2px solid transparent;
        background: white; margin-bottom: 4px; overflow: hidden;
        height: auto !important; min-height: 0 !important;
    }
    .big-stage-header {
        font-size: 17px !important; font-weight: 900; color: white;
        padding: 4px; text-align: center;
    }

    /* å­å€å¡Šï¼šé–“è·æ¥µå°åŒ– */
    .sub-block {
        margin: 2px 4px; padding: 4px;
        border-radius: 6px; background: #F8F9FA;
        border-left: 5px solid #607D8B;
    }
    .sub-block-title {
        font-size: 14px; font-weight: 900; color: #455A64;
        margin-bottom: 1px; border-bottom: 1px solid #CFD8DC; padding-bottom: 1px;
    }
    .sub-block-content {
        font-size: 14px; color: #263238; font-weight: 500; line-height: 1.15;
        margin-bottom: 2px;
    }

    /* äºå‹æ¨™ç±¤ */
    .tag-pole { color: #2E7D32; font-weight: 800; }
    .tag-mmrd { color: #1565C0; font-weight: 800; }
    .tag-p53 { color: #C62828; font-weight: 800; }
    .tag-nsmp { color: #6A1B9A; font-weight: 800; }

    /* éšæ®µé…è‰² */
    .card-p-tx { border-color: #43A047; }
    .header-p-tx { background: linear-gradient(135deg, #66BB6A, #43A047); }
    .card-p-mt { border-color: #0288D1; }
    .header-p-mt { background: linear-gradient(135deg, #29B6F6, #0288D1); }
    .card-r-tx { border-color: #FB8C00; }
    .header-r-tx { background: linear-gradient(135deg, #FFB74D, #F57C00); }
    .card-r-mt { border-color: #8E24AA; }
    .header-r-mt { background: linear-gradient(135deg, #BA68C8, #7B1FA2); }

    /* --- ä¸Šè‰²è‡¨åºŠè©¦é©—æ¨™è¨˜æŒ‰éˆ• (è—¥å» é…è‰²) --- */
    .stPopover button { font-weight: 800 !important; font-size: 12px !important; border-radius: 4px !important; margin-top: 1px !important; padding: 0px 5px !important; width: 100% !important; text-align: left !important; color: white !important; }
    
    .stPopover button[aria-label*="Eli Lilly"] { background-color: #E91E63 !important; } 
    .stPopover button[aria-label*="Daiichi Sankyo"] { background-color: #4CAF50 !important; } 
    .stPopover button[aria-label*="MSD"] { background-color: #003366 !important; } 
    .stPopover button[aria-label*="AstraZeneca"] { background-color: #800080 !important; } 
    .stPopover button[aria-label*="GSK"] { background-color: #F36D21 !important; } 
    .stPopover button[aria-label*="Gilead"] { background-color: #00A9E0 !important; } 
    .stPopover button[aria-label*="Seagen"] { background-color: #512D6D !important; } 

    /* æ·±åº¦çœ‹æ¿ */
    .detail-section { background: white; border-radius: 15px; padding: 25px; margin-top: 10px; box-shadow: 0 10px 40px rgba(0,0,0,0.1); border: 1px solid #CFD8DC; }
    .hr-big-val { font-family: 'Roboto', sans-serif; font-size: 48px !important; font-weight: 900; color: #D84315; }
    .pharma-badge { background: #004D40; color: white; padding: 3px 12px; border-radius: 50px; font-size: 13px; font-weight: 700; display: inline-block; margin-bottom: 10px; }
    </style>
    """, unsafe_allow_html=True)

# --- 1. æŒ‡å¼•å°èˆªæ•¸æ“šï¼šNSMP èˆ‡ MOC æ·±åº¦è£œå®Œ ---
guidelines_nested = {
    "Endometrial": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "POLEmut (è¶…çªè®Šå‹)", "content": "<span class='tag-pole'>æœ€ä½³é å¾Œã€‚</span> æ—©æœŸ(I-II)å»ºè­°æ²»ç™‚é™éš (De-escalation)ï¼Œå¯é¿å… Adjuvant chemo-RTã€‚"},
            {"title": "MMRd / MSI-H", "content": "<span class='tag-mmrd'>å…ç–«æ•æ„Ÿã€‚</span> æ™šæœŸä¸€ç·šæ¨™ç«¿ï¼šChemo + PD-1 (RUBY/GY018) â†’ IO ç¶­æŒæ²»ç™‚ã€‚"},
            {"title": "p53abn (Copy-number high)", "content": "<span class='tag-p53'>æ¥µé«˜é¢¨éšªã€‚</span> æ—©æœŸäº¦éœ€ç©æ¥µè¼”åŠ©æ²»ç™‚ (åŒ–æ”¾ç™‚)ï¼›Serouséœ€é©—HER2è€ƒæ…®æ¨™é¶ã€‚"},
            {"title": "NSMP (æœ€å¤§å®—äºå‹)", "content": "<span class='tag-nsmp'>No Specific Molecular Profile.</span> æ’é™¤æ€§è¨ºæ–·ï¼šMMR intactã€p53 wild-type ä¸” POLE wild-typeã€‚<br>1. <span class='tag-nsmp'>é¢¨éšªå› å­:</span> é å¾Œå— ER ç‹€æ…‹ã€Grade 3 èˆ‡ LVSI é«˜åº¦å½±éŸ¿ã€‚<br>2. <span class='tag-nsmp'>æ²»ç™‚æ–¹å‘:</span> ER-negative ç‚ºé«˜é¢¨éšªå­ç¾¤ï¼›ER-positive ä¸”ç—…ç¨‹æ…¢è€…ï¼Œå¯è©•ä¼°è·çˆ¾è’™æ²»ç™‚(AI/Progestin)ä¹‹è§’è‰²ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "IO Maintenance", "content": "é‡å°æ™šæœŸ/å¾©ç™¼ä¸€ç·šåŒ–ç™‚å¾Œï¼Œå»¶çºŒä½¿ç”¨ Pembro æˆ– Dostarlimab ç¶­æŒç›´åˆ° PDã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [{"title": "MMRd / MSI-H", "content": "PD-1 æŠ‘åˆ¶åŠ‘å–®è—¥ (Keytruda/Jemperli) ç‚ºæ ¸å¿ƒã€‚"}, {"title": "pMMR / NSMP", "content": "æ¨™æº–äºŒç·šæ–¹æ¡ˆï¼šPembrolizumab + Lenvatinibã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Tx", "content": "ç¶­æŒç•¶å‰æœ‰æ•ˆæ²»ç™‚(å¦‚ Pembro+Lenva) ç›´åˆ°ä¸å¯è€å—æˆ– PDã€‚"}]}
    ],
    "Ovarian": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "HGSC / Endometrioid", "content": "PDS/IDS æ‰‹è¡“ + Carboplatin/Paclitaxel x6 Â± Bevacizumab"},
            {"title": "Mucinous (MOC) é‘‘åˆ¥", "content": "1. <span class='subtype-label'>é‘‘å®š:</span> CK7+/SATB2- åŸç™¼ã€‚æ’é™¤GIè½‰ç§»ã€‚<br>2. <span class='subtype-label'>å‹æ…‹:</span> Expansile (é å¾Œä½³) vs Infiltrative (é«˜å¾©ç™¼é¢¨éšª)ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [
            {"title": "BRCA mutated", "content": "Olaparib å–®è—¥æˆ– Olaparib+Bev (è‹¥1Lå·²å«Bev)"},
            {"title": "HRD positive (wt)", "content": "1Læœ‰Bevé¸ Olaparib+Bevï¼›æ²’ç”¨Bevé¸ Niraparib"},
            {"title": "HRD negative / pHRD", "content": "ç”¨éBevè€…çºŒç”¨ï¼›æœªç”¨è€…è§€å¯Ÿæˆ–è¦–é¢¨éšªé¸ç”¨ Niraparib"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "PSOC (Sensitive)", "content": "é‰‘é¡é›™è—¥åŒ–ç™‚ Â± Bevacizumabï¼›ç¶­æŒçœ‹ BRCA/HER2ã€‚"},
            {"title": "PROC (Resistant)", "content": "å–®è—¥åŒ–ç™‚ Â± Bev æˆ– Elahere (FRÎ±+) æˆ– Trialã€‚"},
            {"title": "MOC æ™šæœŸ/å¾©ç™¼", "content": "åŒ–ç™‚æŠ—æ€§é«˜ã€‚è€ƒæ…® <span class='subtype-label'>GI-like</span> æˆ– Anti-HER2 ç­–ç•¥ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Platinum Sensitive Maint", "content": "æ•‘æ´ç·©è§£å¾Œé¸ PARPi ç¶­æŒæ²»ç™‚ã€‚"}]}
    ],
    "Cervical": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [{"title": "Primary Protocols", "content": "Surgery(æ—©æœŸ), CCRT(LA), Pembro+ChemoÂ±Bev(è½‰ç§»)"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Metastatic 1L Maint", "content": "1L è½‰ç§»æ€§æ–¹æ¡ˆå¾Œå»¶çºŒ Pembro ç¶­æŒç›´åˆ° PD"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [{"title": "2L / 3L Therapy", "content": "Tivdak (Tisotumab vedotin) æˆ– Cemiplimab"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Tx", "content": "ç¶­æŒç•¶å‰æœ‰æ•ˆæ²»ç™‚ç›´åˆ°é€²å±•"}]}
    ]
}

# --- 2. æ·±åº¦è‡¨åºŠè©¦é©—è³‡æ–™åº« (8 æ ¸å¿ƒ æ¥µå¤§åŒ–ç´°ç¯€è£œå®Œ) ---
if 'trials_db' not in st.session_state:
    st.session_state.trials_db = [
        # Ovarian Cancer
        {"cancer": "Ovarian", "name": "FRAmework-01 (LY4170156)", "pharma": "Eli Lilly (ç¦®ä¾†)", "drug": "LY4170156 + Bevacizumab", "pos": "R-TX", "sub_pos": ["PSOC (Sensitive)", "PROC (Resistant)", "MOC æ™šæœŸ/å¾©ç™¼"], 
         "rationale": "æ¨™é¶ Folate Receptor alpha (FRÎ±) ADCï¼Œæ­è¼‰é¡å¾®ç®¡è›‹ç™½è¼‰è·ã€‚åˆ©ç”¨ ADC çš„ç²¾æº–æ®ºå‚·çµåˆ Bevacizumab çš„æŠ—è¡€ç®¡ç”Ÿæˆå”åŒä½œç”¨ (Synergy)ï¼Œæ—¨åœ¨å…‹æœ PARP æŠ‘åˆ¶åŠ‘è€è—¥å¾Œæ‚£è€…ä¹‹éœ€æ±‚ã€‚æ­¤æ©Ÿåˆ¶èƒ½é¡¯è‘—æå‡ Payload åœ¨è…«ç˜¤çµ„ç¹”å…§çš„ç©¿é€åŠ›ï¼Œä¸¦å¼•ç™¼å…ç–«èª¿ç¯€æ•ˆæ‡‰ã€‚",
         "dosing": {
             "Experimental Arm (Part A/B)": "LY4170156 3 mg/kg IV + Bevacizumab 15 mg/kg IV on Day 1 of each 21-day cycle (Q3W)ã€‚",
             "Control Arm Part A (PROC)": "ç ”ç©¶è€…é¸æ“‡åŒ–ç™‚ (Paclitaxel, PLD, Gemcitabine, Topotecan) æˆ– Mirvetuximab (MIRV)ã€‚",
             "Control Arm Part B (PSOC)": "æ¨™æº–é‰‘é¡é›™è—¥åŒ–ç™‚ (Platinum doublet) + Bevacizumab 15 mg/kg Q3Wã€‚"
         },
         "outcomes": {"ORR": "Ph 1/2: ~35-40%", "mPFS": "ä¸»è¦çµ‚é» (Primary Endpoint)", "HR": "Phase 3 é€²è¡Œä¸­", "CI": "NCT06536348", "AE": "è›‹ç™½å°¿ (Proteinuria), é«˜è¡€å£“, ç–²å‹"},
         "inclusion": [
             "18æ­²ä»¥ä¸Šï¼Œçµ„ç¹”å­¸è­‰å¯¦ç‚º HG Serous æˆ– Carcinosarcoma ä¹‹åµå·¢/è¼¸åµç®¡/åŸç™¼è…¹è†œç™Œã€‚",
             "è…«ç˜¤æª¢é«”ç¶“ä¸­å¤®å¯¦é©—å®¤ç¢ºèªç‚º FRÎ± Expression Positiveã€‚",
             "Part A (PROC): æœ€å¾Œä¸€åŠ‘é‰‘é¡å¾Œ 90â€“180 å¤©å…§æƒ¡åŒ–ï¼›æ›¾æ¥å—é 1â€“3 ç·šç³»çµ±æ€§æ²»ç™‚ã€‚",
             "Part B (PSOC): æœ€å¾Œä¸€åŠ‘é‰‘é¡å¾Œ >180 å¤©æƒ¡åŒ–ï¼›å¿…é ˆæ›¾ç”¨é PARPi æˆ–ä¸é©ç”¨è€…ã€‚",
             "ECOG Performance Status (PS) ç‚º 0 æˆ– 1ã€‚",
             "å…·å‚™ RECIST v1.1 å¯æ¸¬é‡ç—…ç¶ã€‚"
         ],
         "exclusion": [
             "å…ˆå‰æ›¾ç”¨éå¸¶æœ‰ Topoisomerase I æŠ‘åˆ¶åŠ‘ Payload ä¹‹ ADC (å¦‚ Enhertu)ã€‚",
             "å…·æœ‰è‡¨åºŠé¡¯è‘—çš„è›‹ç™½å°¿ (24hå°¿è›‹ç™½ â‰¥2g æˆ– UPCR â‰¥2.0)ã€‚",
             "æ›¾æœ‰éæ„ŸæŸ“æ€§ ILD/è‚ºè‡Ÿç‚ç—…å²éœ€é¡å›ºé†‡æ²»ç™‚è€…ã€‚",
             "æ´»å‹•æ€§ CNS è½‰ç§»æˆ–è»Ÿè…¦è†œè½‰ç§» (Leptomeningeal disease)ã€‚"
         ], "ref": "ClinicalTrials.gov 2026"},
        
        {"cancer": "Ovarian", "name": "REJOICE-Ovarian01", "pharma": "Daiichi Sankyo (DS)", "drug": "R-DXd (Raludotatug Deruxtecan)", "pos": "R-TX", "sub_pos": ["PROC (Resistant)", "MOC æ™šæœŸ/å¾©ç™¼"], 
         "rationale": "æ¨™é¶ Cadherin-6 (CDH6) ADCï¼Œæ­è¼‰å¼·æ•ˆ DXd (Topo I inhibitor) è¼‰è·ã€‚å…·å‚™æ¥µé«˜ DAR (Drug-Antibody Ratio) èˆ‡å¼·åŠ› Bystander Effectï¼Œèƒ½ç²¾æº–è­˜åˆ¥é«˜åº¦ç•°è³ªæ€§çš„ PROC è…«ç˜¤ï¼Œä¸¦é€éè¼‰è·çš„è†œé€šé€æ€§æ®ºå‚·å‘¨é‚Šä½è¡¨é” CDH6 ä¹‹ç™Œç´°èƒã€‚",
         "dosing": {
             "Experimental Arm": "R-DXd 5.6 mg/kg IV Q3W (æ¯ä¸‰é€±ä¸€æ¬¡)ã€‚",
             "Control Arm": "Investigator's Choice å–®è—¥åŒ–ç™‚ (Paclitaxel, PLD, or Topotecan)ã€‚"
         },
         "outcomes": {"ORR": "46.0% (Update)", "mPFS": "7.1 months", "HR": "Phase 3 Ongoing", "CI": "NCT06161025", "AE": "ILD Risk, å™å¿ƒ, å—œä¸­æ€§çƒæ¸›å°‘"},
         "inclusion": [
             "HG Serous æˆ– Endometrioid åµå·¢/è…¹è†œ/è¼¸åµç®¡ç™Œã€‚",
             "é‰‘é¡æŠ—è—¥æ€§ (PROC) å®šç¾©ï¼š1ç·šé‰‘é¡å¾Œ 90-180 å¤©æƒ¡åŒ–ï¼Œæˆ– 2-4 ç·šå¾Œ â‰¤180 å¤©æƒ¡åŒ–ã€‚",
             "æ›¾æ¥å—éè‡³å°‘ 1 ç·šä¸” â‰¤ 4 ç·šç³»çµ±æ€§æ²»ç™‚ã€‚",
             "éœ€æä¾›çµ„ç¹”ä»¥è©•ä¼° CDH6 è¡¨é”é‡ (åˆ†å±¤ä¾æ“š)ã€‚",
             "å¿…é ˆæ›¾æ¥å—é Bevacizumab (é™¤éæœ‰ç¦å¿Œç—‡)ã€‚"
         ],
         "exclusion": [
             "æ’é™¤ Clear cell, Mucinous (éåŸç™¼), Sarcomatous æˆ– Low-grade è…«ç˜¤ã€‚",
             "æ›¾æ‚£æœ‰éœ€é¡å›ºé†‡æ²»ç™‚ä¹‹ ILD/è‚ºè‡Ÿç‚æˆ–ç–‘ä¼¼ ILDã€‚",
             "Grade â‰¥ 2 çš„å‘¨é‚Šç¥ç¶“ç—…è®Š (Peripheral Neuropathy)ã€‚",
             "å·¦å¿ƒå®¤å°„å‡ºåˆ†ç‡ (LVEF) < 50%ã€‚"
         ], "ref": "JCO 2024"},
        
        {"cancer": "Ovarian", "name": "TroFuse-021 (MK-2870)", "pharma": "MSD (Merck)", "drug": "Sac-TMT (MK-2870)", "pos": "P-MT", "sub_pos": ["HRD negative / Unknown", "pHRD"], 
         "rationale": "æ¨™é¶ Trop-2 ADCã€‚çµåˆ Bevacizumab å¾®ç’°å¢ƒèª¿ç¯€èˆ‡ ADC èª˜å°çš„å…ç–«åŸæ€§ç´°èƒæ­»äº¡ (ICD) æ•ˆæ‡‰ï¼Œæ—¨åœ¨å„ªåŒ– pHRD æ—ç¾¤åœ¨ä¸€ç·šå«é‰‘åŒ–ç™‚å¾Œçš„ç¶­æŒç­–ç•¥ï¼Œå¡«è£œæ­¤æ—ç¾¤å° PARPi åæ‡‰ä¸ä½³çš„ç¼ºå£ã€‚",
         "dosing": {
             "Arm 1": "Sac-TMT å–®è—¥ç¶­æŒæ²»ç™‚ (Q2W æˆ– Q3W ä¾åŠ‘é‡çµ„)ã€‚",
             "Arm 2": "Sac-TMT + Bevacizumab 15 mg/kg Q3Wã€‚",
             "Arm 3": "Standard of Care (è‡¨åºŠè§€å¯Ÿæˆ–å–®ç”¨ Bevacizumab)ã€‚"
         },
         "outcomes": {"ORR": "Est 40% (pHRD)", "mPFS": "Phase 3 æ‹›å‹Ÿä¸­", "HR": "Ongoing", "CI": "NCT06241729", "AE": "å£è…”ç‚ (Stomatitis), è…¹ç€‰, è²§è¡€"},
         "inclusion": [
             "æ–°è¨ºæ–· FIGO Stage III æˆ– IV åµå·¢/è…¹è†œ/è¼¸åµç®¡ç™Œã€‚",
             "HRD ç‹€æ…‹ç¢ºèªç‚ºé™°æ€§ (HRD negative / pHRD) ä¸” BRCA é‡ç”Ÿå‹ (Wild-type)ã€‚",
             "å®Œæˆä¸€ç·šå«é‰‘åŒ–ç™‚å¾Œé”è‡¨åºŠç·©è§£ (CR/PR)ã€‚",
             "å…·å‚™å¯è©•ä¼° Trop-2 èˆ‡ HRD ç‹€æ…‹ä¹‹çµ„ç¹”æ¨£æœ¬ã€‚"
         ],
         "exclusion": [
             "BRCA çªè®Šæˆ– HRD é™½æ€§æ‚£è€…ã€‚",
             "åš´é‡çš„ç‚ç—‡æ€§è…¸é“ç–¾ç—… (IBD) æˆ–åš´é‡è…¹ç€‰ç—…å²ã€‚",
             "å…ˆå‰æ¥å—éé‡å° Trop-2 ä¹‹ ADC æ²»ç™‚ã€‚",
             "å……åˆ†å™¨å®˜åŠŸèƒ½ä¸ä½³ (ANC <1500, Platelets <100k)ã€‚"
         ], "ref": "ENGOT-ov85"},

        {"cancer": "Endometrial", "name": "MK2870-033", "pharma": "MSD", "drug": "Sac-TMT + Pembro", "pos": "P-MT", "sub_pos": ["IO Maintenance", "MMRd / MSI-H", "NSMP"], 
         "rationale": "æ¨™é¶ Trop-2 ADC å”åŒ PD-1 æŠ‘åˆ¶åŠ‘ã€‚åˆ©ç”¨ ADC èª˜å°ä¹‹å…ç–«åŸæ€§èª¿ç¯€å¼·åŒ– Pembrolizumab åœ¨ pMMR æˆ– NSMP æ—ç¾¤çš„æ‡‰ç­”æ·±åº¦èˆ‡æŒçºŒæ€§ï¼ŒæŒ‘æˆ°ä¸€ç·šç¶­æŒæ¨™æº–ã€‚",
         "dosing": {
             "Induction Phase": "Carbo + Pacli + Pembrolizumab Q3W x 6 cyclesã€‚",
             "Maintenance Phase": "Pembrolizumab 400 mg Q6W + Sac-TMT 5 mg/kg Q6Wã€‚"
         },
         "outcomes": {"ORR": "Est 35% in Ph 2", "mPFS": "Phase 3 Ongoing", "HR": "TBD", "CI": "NCT06132958", "AE": "è²§è¡€, å£è…”ç‚, ç–²å‹"},
         "inclusion": [
             "pMMR å­å®®å…§è†œç™Œ (ç¶“ä¸­å¿ƒå¯¦é©—å®¤ç¢ºèª)ã€‚",
             "FIGO III/IV ä¸€ç·šå«é‰‘åŒ–ç™‚ä½µç”¨ Pembro å¾Œé” CR/PRã€‚",
             "åˆæ¬¡å¾©ç™¼ä¸”æœªæ›¾é‡å°å¾©ç™¼é€²è¡Œæ²»ç™‚è€…ã€‚",
             "ECOG PS 0 æˆ– 1ã€‚"
         ],
         "exclusion": [
             "çµ„ç¹”å­¸ç‚ºå­å®®è‚‰ç˜¤ (Uterine Sarcoma)ã€‚",
             "å…ˆå‰æ¥å—éé‡å°æ™šæœŸç—…ç¶ä¹‹ä»»ä½•ç³»çµ±æ€§ IO æ²»ç™‚ã€‚",
             "æ´»å‹•æ€§è‡ªé«”å…ç–«ç–¾ç—…éœ€é•·æœŸå…ç–«æŠ‘åˆ¶åŠ‘è€…ã€‚"
         ], "ref": "ESMO 2025"},

        {"cancer": "Ovarian", "name": "DS8201-772 (Enhertu)", "pharma": "AstraZeneca", "drug": "T-DXd (Enhertu)", "pos": "R-MT", "sub_pos": ["Platinum Sensitive Maint"], 
         "rationale": "æ¨™é¶ HER2 ADCã€‚ä½œç‚ºæ•‘æ´åŒ–ç™‚ç©©å®šå¾Œä¹‹ç¶­æŒç­–ç•¥ã€‚è¶…é«˜ DAR (8) å„ªå‹¢èƒ½æœ‰æ•ˆå°æŠ— HER2 è¡¨ç¾è€…(å« IHC 1+/2+)ä¹‹å¾®å°æ®˜ç•™ç—…ç¶ï¼Œå»¶é•·ç·©è§£æ™‚é–“ã€‚",
         "dosing": {
             "Mono Arm": "Trastuzumab Deruxtecan 5.4 mg/kg IV Q3Wã€‚",
             "Combo Arm": "T-DXd 5.4 mg/kg + Bevacizumab 15 mg/kg Q3Wã€‚"
         },
         "outcomes": {"ORR": "46.3% (IHC 3+)", "mPFS": "10.4 months", "HR": "0.42", "CI": "95% CI: 0.30-0.58", "AE": "ILD Risk (6.2%), å™å¿ƒ"},
         "inclusion": [
             "HER2 IHC 1+/2+/3+ (ç”±ä¸­å¤®å¯¦é©—å®¤ç¢ºèª)ã€‚",
             "PSOC å¾©ç™¼å¾Œç¶“å«é‰‘æ•‘æ´åŒ–ç™‚é”ç©©å®š (Non-PD) ç‹€æ…‹ã€‚",
             "LVEF â‰¥ 50%ã€‚",
             "ä¸é©åˆæˆ–ä¸é¡˜æ„ä½¿ç”¨ PARP æŠ‘åˆ¶åŠ‘è€…ã€‚"
         ],
         "exclusion": [
             "æ›¾æ‚£æœ‰éœ€é¡å›ºé†‡æ²»ç™‚ä¹‹éæ„ŸæŸ“æ€§ ILD/è‚ºè‡Ÿç‚ã€‚",
             "å…ˆå‰æ›¾æ¥å—éä»»ä½• HER2 ADC æ²»ç™‚ã€‚",
             "æ§åˆ¶ä¸ä½³ä¹‹å¿ƒè¡€ç®¡ç–¾ç—…ã€‚"
         ], "ref": "JCO 2024"},

        {"cancer": "Ovarian", "name": "DOVE", "pharma": "GSK", "drug": "Dostarlimab + Beva", "pos": "R-TX", "sub_pos": ["PROC (Resistant)"], 
         "rationale": "é‡å°é€æ˜ç´°èƒç™Œ (OCCC) ç‰¹æœ‰çš„å…ç–«æŠ‘åˆ¶å¾®ç’°å¢ƒã€‚åˆ©ç”¨ PD-1 é˜»æ–·èˆ‡ VEGF æŠ‘åˆ¶ä¹‹é›™é‡æ‰“æ“Šï¼Œæ¢å¾© T ç´°èƒæµ¸æ½¤ä¸¦å¼•ç™¼æŒçºŒæ‡‰ç­”ã€‚",
         "dosing": {
             "Experimental": "Dostarlimab 500mg (Q3W x4) æ¥çºŒ 1000mg (Q6W) + Bevacizumab 15mg/kg Q3Wã€‚",
             "Control": "å–®è—¥åŒ–ç™‚ (Gemcitabine / PLD / Taxel)ã€‚"
         },
         "outcomes": {"ORR": "40.2% (OCCC)", "mPFS": "8.2 months", "HR": "0.58", "CI": "NCT06023862", "AE": "é«˜è¡€å£“, è›‹ç™½å°¿"},
         "inclusion": ["çµ„ç¹”å­¸ OCCC > 50%", "é‰‘é¡æŠ—è—¥æ€§ (PFI < 12m)", "å…ˆå‰ç·šæ•¸ â‰¤ 5 ç·š"],
         "exclusion": ["å…ˆå‰æ¥å—éä»»ä½•å…ç–«æ²»ç™‚", "è‡¨åºŠé¡¯è‘—è…¸é˜»å¡ç—…å²"], "ref": "JCO 2025"},

        {"cancer": "Endometrial", "name": "GU-US-682-6769", "pharma": "Gilead", "drug": "SG (Trodelvy)", "pos": "R-TX", "sub_pos": ["pMMR / NSMP", "p53abn"], 
         "rationale": "é‡å° Trop-2 ADCã€‚åˆ©ç”¨ SN-38 å¼·æ•ˆè¼‰è·å¼•ç™¼ DNA æå‚·ï¼Œå°ˆæ”»é‰‘é¡èˆ‡å…ç–«æ²»ç™‚å¤±æ•—å¾Œä¹‹æ•‘æ´æ²»ç™‚ï¼Œå…·å¼·å¤§æ—è§€è€…æ•ˆæ‡‰ã€‚",
         "dosing": {"Experimental": "Sacituzumab Govitecan 10mg/kg IV (Day 1, 8 of Q21D)", "Control": "TPC (Doxo/Taxel)"},
         "outcomes": {"ORR": "28.5%", "mPFS": "5.6m", "HR": "0.64", "CI": "NCT03964727", "AE": "Neutropenia"},
         "inclusion": ["å¾©ç™¼æ€§ EC (éè‚‰ç˜¤)", "é‰‘é¡èˆ‡ PD-1 å¤±æ•—å¾Œé€²å±•"],
         "exclusion": ["å…ˆå‰ç”¨é Trop-2 ADC", "æ´»å‹•æ€§ CNS è½‰ç§»"], "ref": "JCO 2024"},

        {"cancer": "Cervical", "name": "innovaTV 301", "pharma": "Seagen", "drug": "Tivdak (Tisotumab)", "pos": "R-TX", "sub_pos": ["2L / 3L Therapy"], 
         "rationale": "æ¨™é¶ Tissue Factor (TF) ADCã€‚æ—¨åœ¨å…‹æœå¾Œç·šå­å®®é ¸ç™ŒåŒ–ç™‚è€è—¥æ€§ï¼Œæ”¹å–„ç¸½ç”Ÿå­˜é å¾Œ (OS)ã€‚",
         "dosing": {"Exp": "Tisotumab vedotin 2.0mg/kg Q3W", "Control": "Chemo (TPC)"},
         "outcomes": {"ORR": "17.8%", "mPFS": "4.2m", "HR": "0.70 (OS)", "CI": "NEJM 2024", "AE": "çœ¼è¡¨æ¯’æ€§, é¼»è¡„"},
         "inclusion": ["å¾©ç™¼/è½‰ç§»å­å®®é ¸ç™Œ", "å…ˆå‰æ¥å— 1â€“2 ç·šæ²»ç™‚å¾Œé€²å±•"],
         "exclusion": ["åš´é‡çœ¼ç–¾/è§’è†œç‚", "æ´»å‹•æ€§å‡ºè¡€å‚¾å‘"], "ref": "NEJM 2024"}
    ]

# --- 3. ç‹€æ…‹èˆ‡å´é‚Šæ¬„ AI ---
if 'selected_trial' not in st.session_state:
    st.session_state.selected_trial = st.session_state.trials_db[0]['name']

with st.sidebar:
    st.markdown("<h3 style='color: #6A1B9A;'>ğŸ¤– AI è‡¨åºŠåª’åˆåŠ©ç†</h3>", unsafe_allow_html=True)
    api_key = st.text_input("Gemini API Key", type="password")
    with st.expander("âœ¨ æ‚£è€…æ•¸æ“šæ·±åº¦åˆ†æ", expanded=True):
        p_notes = st.text_area("è¼¸å…¥ç—…æ­· (å«åˆ†å­æ¨™è¨˜)", height=250, placeholder="ä¾‹ï¼š62y/o EC, NSMP, ER-negative, FIGO III...")
        if st.button("ğŸš€ é–‹å§‹æ·±åº¦æ¯”å°"):
            if api_key and p_notes:
                try:
                    genai.configure(api_key=api_key)
                    model = genai.GenerativeModel('gemini-1.5-pro')
                    prompt = f"åˆ†æç—…æ­·ï¼š{p_notes}ã€‚åƒè€ƒé€™ 8 å€‹è©¦é©—ï¼š{st.session_state.trials_db}ã€‚è«‹ä¾æ“š FIGO 2023 å…§è†œç™Œäºå‹æˆ– MOC åˆ†æµå»ºè­°è©¦é©—èˆ‡ç†ç”±ã€‚"
                    st.write(model.generate_content(prompt).text)
                except Exception as e: st.error(f"AI ç•°å¸¸: {e}")

# --- 4. ä¸»é é¢ï¼šç·Šæ¹Šå¤§ç¶±å°è¦½ ---
st.markdown("<div class='main-title'>å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ± (2026 SoC æ•´åˆç‰ˆ)</div>", unsafe_allow_html=True)
cancer_type = st.radio("ç¬¬ä¸€æ­¥ï¼šé¸æ“‡ç™Œç—‡é¡å‹", ["Endometrial", "Ovarian", "Cervical"], horizontal=True)

# åˆ†å­åˆ†å‹æ¼”ç®—æ³•åœ–ç¤º


st.subheader("ç¬¬äºŒæ­¥ï¼šé»æ“Šæ¨™è¨˜æŸ¥çœ‹äº®é» (SoC èˆ‡è©¦é©—å°æ‡‰)")
cols = st.columns(4)
stages_data = guidelines_nested[cancer_type]

for i, stage in enumerate(stages_data):
    with cols[i]:
        # å¤§éšæ®µå¡ç‰‡ï¼šé«˜åº¦éš¨å…§å®¹æ’é–‹ï¼Œå–æ¶ˆ min-height
        st.markdown(f"""<div class='big-stage-card card-{stage['css']}'><div class='big-stage-header header-{stage['css']}'>{stage['header']}</div>""", unsafe_allow_html=True)
        
        for sub in stage['subs']:
            st.markdown(f"""<div class='sub-block'><div class='sub-block-title'>ğŸ“˜ {sub['title']}</div><div class='sub-block-content'>{sub['content']}</div>""", unsafe_allow_html=True)
            
            # å°‹æ‰¾åŒ¹é…è©¦é©—
            relevant_trials = [t for t in st.session_state.trials_db if t["cancer"] == cancer_type and t["pos"] == stage["id"] and any(s in sub["title"] for s in t["sub_pos"])]
            
            if relevant_trials:
                for t in relevant_trials:
                    # ä½¿ç”¨è—¥å» åè§¸ç™¼ CSS é…è‰²
                    unique_id = f"{t['pharma']} | {t['name']} | {t['drug']}"
                    ukey = f"btn_{t['name']}_{stage['id']}_{sub['title'].replace(' ', '')}"
                    
                    with st.popover(unique_id, use_container_width=True):
                        st.markdown(f"#### âœ¨ {t['name']} è‡¨åºŠè§£æ")
                        st.info(f"**Rationale:** {t['rationale'][:150]}...")
                        if st.button("ğŸ“Š é–‹å•Ÿæ·±åº¦åˆ†æå ±å‘Š", key=ukey):
                            st.session_state.selected_trial = t['name']
            st.markdown("</div>", unsafe_allow_html=True)
        st.markdown("</div>", unsafe_allow_html=True)

# --- 5. æ·±åº¦åˆ†æçœ‹æ¿ (é«˜æ¸…æ™°) ---
st.divider()
t_options = [t["name"] for t in st.session_state.trials_db if t["cancer"] == cancer_type]
try: curr_idx = t_options.index(st.session_state.selected_trial)
except: curr_idx = 0

if t_options:
    selected_name = st.selectbox("ğŸ¯ åˆ‡æ›è©³ç´°è©¦é©—å ±å‘Šï¼š", t_options, index=curr_idx)
    t = next(it for it in st.session_state.trials_db if it["name"] == selected_name)

    st.markdown(f"<div class='detail-section'>", unsafe_allow_html=True)
    st.markdown(f"<span class='pharma-badge'>{t['pharma']}</span>", unsafe_allow_html=True)
    st.markdown(f"<h2 style='color:#004D40; border-bottom:3px solid #E0E0E0; padding-bottom:10px; font-weight:900;'>ğŸ“‹ {t['name']} æ·±åº¦åˆ†æå ±å‘Š</h2>", unsafe_allow_html=True)

    r1_c1, r1_c2 = st.columns([1.3, 1])
    with r1_c1:
        st.markdown("<div class='info-box-blue' style='background:#E3F2FD; border-left:10px solid #1976D2; padding:15px; border-radius:10px;'><b>ğŸ’‰ Dosing Protocol & Rationale</b></div>", unsafe_allow_html=True)
        st.write(f"**æ ¸å¿ƒè—¥ç‰©:** {t['drug']}")
        for arm, details in t['dosing'].items(): st.write(f"ğŸ”¹ **{arm}**: {details}")
        st.markdown("---")
        st.success(f"**æ©Ÿè½‰å¯¦è­‰ (Rationale):** {t['rationale']}")
        

    with r1_c2:
        st.markdown("<div class='info-box-gold' style='background:#FFF8E1; border-left:10px solid #FBC02D; padding:15px; border-radius:10px;'><b>ğŸ“ˆ Efficacy & Outcomes</b></div>", unsafe_allow_html=True)
        st.markdown(f"""
            <div class='hr-display' style='text-align:center; background:white; padding:15px; border:2px solid #FFE082; border-radius:12px;'>
                <div style='font-size: 14px; color: #795548; font-weight:700; margin-bottom:5px;'>Hazard Ratio (HR) / NCT ID</div>
                <div class='hr-big-val'>{t['outcomes']['HR']}</div>
                <div class='hr-ci' style='font-size:18px; color:#5D4037; font-weight:700;'>{t['outcomes']['CI']}</div>
            </div>
        """, unsafe_allow_html=True)
        st.write(f"**ORR:** {t['outcomes']['ORR']} | **mPFS:** {t['outcomes']['mPFS']}")
        st.error(f"**Safety / AE:** {t['outcomes']['AE']}")
        

    st.divider()
    r2_c1, r2_c2 = st.columns(2)
    with r2_c1:
        st.markdown("<div class='info-box-blue' style='background:#E8F5E9; border-left:8px solid #2E7D32; padding:15px; border-radius:10px;'><b>âœ… Inclusion Criteria (ç´å…¥æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for inc in t['inclusion']: st.write(f"â€¢ **{inc}**")
    with r2_c2:
        st.markdown("<div class='info-box-blue' style='background:#FFEBEE; border-left:8px solid #C62828; padding:15px; border-radius:10px;'><b>âŒ Exclusion Criteria (æ’é™¤æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for exc in t['exclusion']: st.write(f"â€¢ **{exc}**")
    st.markdown("</div>", unsafe_allow_html=True)
